Daxxify neurotoxin recently FDA-approved for frown line treatment

By: Dr. Sean Delaney


Biotechnology company Revance  issued a press release this month announcing the FDA approval of Daxxify  (DaxibotulinumtoxinA-Ianm) for the treatment of frown lines. 

Findings from clinical trials using Daxxify found the average duration of action of the neurotoxin at approximately 6 months, compared to 3~4 months of other neurotoxins, such as Botox  and Dysport , while enjoying a similar safety profile. 

This is very promising news indeed, if our patients can enjoy year-long results with as few as two treatments per year using Daxxify.

Reserve your spot by phone (713) 526-5665 or email [email protected] if you are interested in trying Daxxify when it becomes commercially available.

* All information subject to change. Images may contain models. Individual results are not guaranteed and may vary.